Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Time and Motion Study of Trastuzumab Subcutaneous (SC) and Intravenous (IV) Formulations for the Treatment of Patients With HER2-Positive Early Breast Cancer (EBC)

NCT02658461 is registered in ClinicalTrials.gov with Hoffmann-La Roche as lead sponsor.

NCT NCT02658461
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02658461 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Time and Motion Study of Trastuzumab Subcutaneous (SC) and Intravenous (IV) Formulations for the Treatment of Patients With HER2-Positive Early Breast Cancer (EBC)
Lead sponsor
Hoffmann-La Roche
Phase
Observational
Overall status
Completed
Start date
February 29, 2012
Completion date
February 28, 2013
Enrollment
36 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer